Department of Neuropathology and Neuroscience, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.
PLoS One. 2013 May 7;8(5):e64050. doi: 10.1371/journal.pone.0064050. Print 2013.
Sphingosine-1-phosphate (S1P) is a pluripotent lipophilic mediator working as a ligand for G-protein coupled S1P receptors (S1PR), which is currently highlighted as a therapeutic target for autoimmune diseases including relapsing forms of multiple sclerosis. Sphingosine related compounds, FTY720 and KRP203 known as S1PR modulators, are phosphorylated by sphingosine kinase 2 (SphK2) to yield the active metabolites FTY720-P and KRP203-P, which work as functional antagonists for S1PRs. Here we report that FTY720 and KRP203 decreased production of Amyloid-β peptide (Aβ), a pathogenic proteins causative for Alzheimer disease (AD), in cultured neuronal cells. Pharmacological analyses suggested that the mechanism of FTY720-mediated Aβ decrease in cells was independent of known downstream signaling pathways of S1PRs. Unexpectedly, 6-days treatment of APP transgenic mice with FTY720 resulted in a decrease in Aβ40, but an increase in Aβ42 levels in brains. These results suggest that S1PR modulators are novel type of regulators for Aβ metabolisms that are active in vitro and in vivo.
鞘氨醇-1-磷酸(S1P)是一种多功能亲脂性介质,作为 G 蛋白偶联 S1P 受体(S1PR)的配体,目前被认为是包括多发性硬化症在内的自身免疫性疾病的治疗靶点。鞘氨醇相关化合物 FTY720 和 KRP203 被称为 S1PR 调节剂,它们被鞘氨醇激酶 2(SphK2)磷酸化,生成活性代谢物 FTY720-P 和 KRP203-P,它们作为 S1PR 的功能拮抗剂起作用。在这里,我们报告 FTY720 和 KRP203 可减少培养神经元细胞中淀粉样β肽(Aβ)的产生,Aβ是导致阿尔茨海默病(AD)的致病蛋白。药理分析表明,FTY720 在细胞中介导的 Aβ减少的机制与 S1PR 的已知下游信号通路无关。出乎意料的是,FTY720 对 APP 转基因小鼠的 6 天治疗导致大脑中 Aβ40 减少,但 Aβ42 水平增加。这些结果表明,S1PR 调节剂是 Aβ代谢的新型调节剂,在体外和体内均具有活性。